Fixing the Coverage Gap After Incarceration

May 8th 2022

Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail.

FDA Updates for the Week of May 2, 2022

May 7th 2022

The FDA has approved a rare disease therapy and an additional indication for Enhertu, and grants priority review for Imfinzi in biliary tract cancer. Regulators have issued complete response letters for three therapies. The agency also has scheduled an advisory committee for Nuplazid in Alzheimer’s psychosis.

Brand-name drug prices weigh heavily on Part D beneficiaries

May 6th 2022

Beauty may be in the eye of the beholder, but drug price trends are in the way you crunch the numbers.

2022 Asembia Specialty Pharmacy Summit: Attendees Feasted on a Buffet of Topics

May 6th 2022

Politics and policies were among the main topics at the meeting in Las Vegas. But the 6,000 attendees also heard about biosimilars, the gross-to-net price gap and the ripple effects of the CMS’ Aduhelm coverage decision.

Individualizing UF Therapy

May 6th 2022

Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.